When Support Misses the Bottleneck

The subject now is the failure surface in an incubation decision: what it means when a startup joins a programme but does not accelerate. The practical task is differential diagnosis, not assigning blame. A programme may miss the startup’s real need, deliver a useful offer at an unusable dose, improve readiness while another constraint remains, or be judged against an outcome it was never designed to affect. Separating those possibilities gives founders and policymakers a way to decide whether to adapt the support, seek a different one, or stop treating the incubator as the solution.

Start with the symptom, not the verdict

“The programme did not accelerate us” is a real observation, but it is not yet a cause. It compresses several questions into one sentence. Did the startup enter the programme with an important gap in investment readiness? Did the support address that gap? Did the founders have enough time and access to use it? Did anything change in their capability or evidence? If something did change, was that change connected to the outcome the founders actually needed?

The first possible diagnosis is mismatch. The startup may need customer validation, technical testing, distribution, a missing team capability, or a relationship in a particular market, while the programme is strongest at general training or investor presentation. The OECD’s emphasis on personalisation is relevant here: support should address evolving needs, and a mismatch can deter engagement or be counterproductive. A programme can be well run in its own terms and still be the wrong instrument for a particular company.

Mismatch is not always obvious at admission. A startup’s stated goal may be to raise finance because financing feels like the most visible obstacle. A closer examination may show that investors are hesitating because the proposition has weak evidence of demand, the team lacks a necessary capability, or the company cannot yet explain its market. In that case, investor introductions may be downstream of the real problem. The founders may need a more basic experiment before they need a larger network.

The second possible diagnosis is insufficient dose. A programme may contain the right service but not deliver enough of it to change behaviour. The documented investment-readiness intervention makes this distinction visible: most treatment firms completed its online platform, fewer received individual mentoring, and fewer still attended an in-person masterclass. The online comparison group also showed a gap between accessing the course and completing its quizzes. A startup can truthfully say that it joined and that the programme offered help, while still receiving too little relevant work for a material change to occur.

Dose is partly a programme design question and partly a participation question. Founders in the study cited time away from their businesses and travel distance as important reasons for missing in-person activity. Those constraints are not evidence of indifference. They are part of the operating environment in which the intervention must work. A support format that requires a founder to leave early customers or a second job may have a high opportunity cost. A virtual option may remove travel, but the programme still needs a way to supply feedback, accountability, and relevant interaction.

The third possible diagnosis is a failure of transfer. The startup may have received and used the service, and an intermediate measure may have improved, without the improvement reaching a business outcome. A clearer pitch can be a real gain while customers remain unconvinced. A more disciplined financial plan can be useful while the company still lacks distribution.